H
eart transplantation is currently the best treatment for patients with end-stage heart failure. With the development of more potent immunosuppression, the 1-year survival rate has risen to 85% in the United Kingdom. 1 However, immunosuppressive drugs have several metabolic, infectious, renal, and neoplastic side effects 2 and have not prevented the development of cardiac allograft vasculopathy (CAV), the main limitation of long-term survival of heart transplant recipients. [3] [4] [5] Histologically, CAV presents as a complex interplay between proliferative myoblasts, macrophages, and T lymphocytes leading to the formation of a neointima. 5 There is a need to understand the factors that are responsible for CAV to develop targeted treatment to prevent it.
Following heart transplantation, the cytokine milieu that results because of ischemia/reperfusion injury activates donor passenger leukocytes (DPLs) to migrate out of the graft. 6 DPLs can traffic in the blood circulation to the spleen via reverse transmigration where they can elicit an immune response. 7 Alternatively, they can traffic to draining lymph nodes (dLNs) via lymphatic vessels. During transplantation, donor lymphatic vessels are not reconnected to those of the recipient; this period coincides with the priming of the alloimmune response. 8 It is hypothesized that the accelerated coronary atherosclerosis seen in heart transplant recipients is a result of this interrupted lymphatic drainage after surgery. 9 Our laboratory has demonstrated that DPLs that exit the donor graft via the severed ends of donor lymphatic vessels are taken up by recipient lymphatic capillaries and traffic to recipient dLNs where they elicit a donorspecific T-cell-driven immune response. 8 In our model of mouse heterotopic cardiac transplantation, reconnection of donor lymphatic vessels to those of the recipient occurred by 4 weeks. 8 In the context of inflammation, remodeling of lymphatics within the donor organ posttransplantation occurs by lymphangiogenesis and can be divided into (1) reconnection of donor lymphatics to those of the recipient, and (2) de novo neogenesis, [10] [11] [12] because of the infiltration of macrophages expressing LYVE-1, Prox-1, VEGFR-3, and VEGF-C. 12 Both mechanisms are likely to influence the lymphatic flow rate from the donor graft, which may influence the subsequent immune response. Studies of lymphangiogenesis have mainly focused on renal and corneal, rather than cardiac allograft models 10, 11 or have not investigated lymphatic flow. 4, 13 Therefore, translation of the processes of lymphangiogenesis into a model of heterotrophic cardiac transplantation, in addition to the investigation of lymphatic flow, in this study is novel.
Although the density and size of lymphatic vessels in transplanted hearts have been shown to increase in preclinical models, 4 ,13 the implications are not clear for clinical cardiac transplant samples, where increased lymphatic density has been linked to both rejection 14, 15 and tolerance. 16 Crucially, whether lymphangiogenesis and increased lymphatic vessel density observed following cardiac transplantation does lead to increased lymphatic flow and cellular trafficking is unknown because of the lack of objective quantitative measurement of lymph flow after transplantation. Although increased lymphatic vessel density could enhance DPL trafficking, antigen presentation, and alloimmunity, decreased lymphatic vessel density could lead to edema, which accompanies acute organ rejection in many cases. 17 Whether changes in lymphatic density detected on histological studies are the cause or effect of the immune process is unknown. Furthermore, the effects of transplant rejection itself on the structure, and more importantly, the function of lymphatic vessels remains unclear. Therefore, whether lymphangiogenesis is beneficial or detrimental to graft survival is not clear.
Here, we used single-photon emission computed tomography/computed tomography (SPECT/CT) lymphoscintigraphy to provide objective quantification of lymphatic flow in a preclinical model of chronic heart transplant
Clinical Perspective
What Is New?
• Up to 10% to 12% of cardiac transplant recipients develop cardiac allograft vasculopathy (CAV) each year, making CAV the leading cause of death in patients >5 years posttransplantation.
• It is hypothesized that CAV results because of interrupted lymphatic drainage postsurgery.
• Despite this, the lymphatic network of the heart and its role in transplant rejection has been largely neglected.
• In this study, we used single photon emission computed tomography/computed tomography lymphoscintigraphy in a preclinical model providing an objective quantification of lymphatic flow following transplantation that could be correlated to CAV, demonstrating that cardiac lymphatic remodeling and lymphatic transport dysfunction posttransplant is associated with CAV and transplant rejection.
What Are the Clinical Implications?
• Despite advances in graft survival, there is still a real need for targeted eradication of CAV.
• Our findings indicate that lymphatic flow is increased during chronic rejection. This, in turn, may result in enhanced trafficking of antigen-presenting cells to the local draining lymph nodes and an augmented alloimmune response.
• Although the cause and effect of this phenomenon are yet to be fully established, our data provide the impetus for the investigation of lymphangiogenesis inhibition as a means to dampen chronic rejection.
rejection and correlated it with graft damage and inflammatory infiltrates to investigate the link between functional lymphatic flow and the alloimmune process. 18, 19 in which EYFP is expressed ubiquitously, were bred in house. Animals were kept in specific pathogen-free animal facilities and used in accordance with the Animals (Scientific Procedures) Act 1986.
METHODS

Animals
Cardiac Transplantation
Heterotopic cardiac allografts into the abdomen were performed as previously described, 20, 21 and grafts were monitored by palpation 22 (see Methods in the online-only Data Supplement).
SPECT/CT Lymphoscintigraphy
At 1, 5, or 10 weeks after transplantation, under general anesthesia, the donor hearts were exposed. Nanocoll (GE Healthcare), consisting of 30 MBq of Technetium-99 m-labeled human albumin nanoparticle in 0.1 mL saline, was injected directly into the left ventricular wall at the apex. Injection of Nanocoll is a validated approach to detect lymphatic flow in humans. The incision was then closed and the animals positioned in a nanoSPECT/CT preclinical imager (Bioscan Inc) imaged as described previously. 8 SPECT/CT images are taken after injection of Nanocoll into the apex of transplanted hearts. After the final scan, the mice were euthanized, and the donor heart graft and the recipient's dLN were harvested. With the use of the Invivoscope software (Bioscan, Inc), a sphere is drawn around each region of interest for quantification of the level of radioactivity within the sphere ( Figure 1J ; blue and red sphere). The concentration of radiation determined (Invivoscope software) to be present (MBq) at both scan times is decay corrected to the initial time of the injection of the Nanocoll. The decay-corrected values are used to quantify the lymphatic flow index ( Figure 1K ). Heterotopic transplantation of donor hearts in this model results in donor lymph draining into the mediastinal (m) dLN of the recipients. Scanning of heart recipients at multiple time points after injection of Nanocoll allows quantification of the rate of accumulation of radioactivity in the mdLN as a percentage of the injected dose into the myocardium, providing an objective measurement of lymphatic function, the lymphatic flow index (LFI) ( Figure 1J through 1L ). Although this does not give an absolute measurement of lymphatic flow, it provides an objective quantitative assessment of the lymphatic function of the transplanted organ.
Evans Blue Dye Injection
Ten microliters of 0.5% wt/vol Evans Blue (Sigma-Aldridge) dye was injected into the left ventricular wall of the donor hearts at the apex. Twenty minutes later, the recipient mouse was dissected to directly visualize the pattern of lymph drainage so that the dLN could be identified.
Immunohistochemistry
Donor grafts were harvested and processed for immunohistochemistry; sections were stained with antibodies against CD4 (BD Pharmingen), CD8 (BD Pharmingen), CD68 (Serotec), or LYVE1 (Abcam plc), as previously described 23 (see Methods in the online-only Data Supplement). To determine the crosssectional area of the lymphatic vessels, images of medium power field of view were analyzed with Image J software. To determine if vessels were donor or recipient in origin, staining of lymphatic vessels was performed using a modified protocol. The recipient EYFP cell signal was amplified with fluorescein isothiocyanate-conjugated goat anti-YFP (Abcam plc) as described in Methods in the online-only Data Supplement.
Histology
Donor heart graft tissue was harvested and graft vasculopathy was confirmed by Elastic Van Gieson staining (SigmaAldridge), which was performed per the manufacturer's instructions as described previously 5 (see Methods in the online-only Data Supplement).
Quantitative Polymerase Chain Reaction
Genomic DNA from dLNs was isolated using a DNeasy Blood & Tissue extraction kit per the manufacturer's instructions (Qiagen). DNA concentration was quantified with a Nanodrop ND-1000 spectraphotometer. The Y-chromosome-specific gene, Zfy1, was amplified using quantitative real-time polymerase chain reaction. The presence of male donor-derived cells in the female recipient dLN was calculated against a standard curve of a known percentage of male DNAs as previously reported 24, 25 (see Methods in the online-only Data Supplement).
Statistics
Normality of distributions was calculated using the D'Agostino and Pearson and the Shapiro-Wilk normality tests to determine further statistical analysis. For Figure 1 , the Mann-Whitney U test was used to test for significance between the LFI and loss of radiation from the graft between HY-mismatched and sex-matched transplant recipients. For Figures 2 through 4, the Student t test was used to test for statistical differences between lymphatic vessel size and area and infiltrating inflammatory cell scores from different experimental groups. The statistical differences between time points for these data sets were analyzed by a 2-way ANOVA. Allograft immunohistochemical and genomic data were correlated to LFI using regression analyses (linear, R
2
) and the Spearman rank correlation coefficient (r s ), using GraphPad Prism 7 (GraphPad Software). Groups ranged from n=4 to 7.
RESULTS
Increased LFI in Minor Antigen Mismatched Heart Grafts Undergoing Chronic Rejection
Although structural changes of lymphatic vessels in donor grafts have been documented, objective measurement of the lymphatic function is lacking. We ORIGINAL RESEARCH ARTICLE therefore used SPECT/CT lymphoscintigraphy developed in our laboratory 8 and extended it to give quantitative data on lymphatic flow after transplantation. SPECT/CT lymphoscintigraphy was performed on female EYFP C57BL/6 recipient mice that had received either wild-type male or sex-matched C57BL/6 donor hearts ( Figure 1 ). Sex-mismatched male grafts express the male antigen HY, a minor histocompatibility antigen recognized by the female recipient. This antigen evokes a chronic rejection response, 26 resulting in CAV. Recipients underwent injection of Nanocoll directly into the donor myocardium at the apex and SPECT/ 
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CT lymphoscintigraphy. At week 1, reconnection of donor lymphatic vessels to that of the recipient will not have occurred. Scanning was also conducted at week 5 because we have previously shown that reconnection of the donor lymphatic vessels occurred by 4 weeks. 8 Week 10 was also chosen to study the effect of de novo neogenesis, within the donor graft, on lymphatic flow. Significant CAV would have developed by this time as well.
In this model, lymph flow from the donor organ drains into the mdLN, which was observed at 4 hours, at week 1, in the sex-matched grafts ( Figure 1A ) and HY-mismatch grafts ( Figure 1B) ; in the HY-mismatch grafts at week 5 ( Figure 1D , Movie I in the online-only Data Supplement) and week 10 ( Figure 1F ). However, in the sex-matched grafts, no radioactivity was observed in the mdLN at week 5 ( Figure 1C , Movie II in the online-only Data Supplement) or week 10 ( Figure 1E ).
To provide direct visual evidence of increased lymph drainage 10 weeks after transplantation in HY-mismatched donor grafts in comparison with sex-matched grafts, Evan blue, a dye used to track lymph flow, was injected into the donor hearts at the apex instead of Nanocoll. Figure 1G through 1I shows that, indeed, the blue dye can be seen in mdLN above the native heart (white arrow) of recipients of HY-mismatched grafts ( Figure 1G through 1H and Figure I in the online-only Data Supplement, yellow arrows), but not in that of recipients of sex-matched grafts ( Figure 1I ).
Scanning of heart recipients at multiple time points after Nanocoll injection allows calculation of the rate of radioactivity accumulation into the mdLN ( Figure 1J to 1K) and therefore the LFI ( Figure 1L ), in addition to quantifying the loss of radiation from the injected graft ( Figure 1M ). Figure 1L shows that the LFI is higher at 1 week after transplantation in both graph types, presumably because of enhanced lymphatic leakage via the severed donor lymphatics. The LFI was higher in the sex-matched grafts than in the HY-mismatched grafts at 35.093 versus 10.361×10
-3 % h -1 , respectively (P=0.0080; Figure 1L ). The situation is reversed at weeks 5 and 10 ( Figure 1L ), when lymph flow from sexmatched grafts had virtually ceased. The LFI at week 5 was below the limit of detection 0 versus 22.329×10
, for the sex-matched versus the HY-mismatched grafts, respectively (P=0.0286), and at week 10, 0 versus 0.88867×10 -3 % h -1 , respectively (P=0.0156). To confirm that the observed changes, especially the virtual cessation of lymph flow from sex-matched grafts at weeks 5 and 10, were not attributable to lymph flowing to other lymph nodes not highlighted in the scan, we quantified the loss of radioactivity from the graft ( Figure 1M) . Indeed, at 10 weeks after transplant, 4 hours after injection of Nanocoll, although only 72.1±12.02% of injected radioactivity remains within the graft of HY-mismatched recipients, virtually all (98.7±0.64%) of injected radioactivity has remained within the sex-matched grafts (P=0.0286), confirming that the rate of lymphatic flow from sex-matched grafts was indeed very low in comparison with sex-mismatched grafts.
Chronic Rejection Is Associated With Myocardial Lymphangiogenesis
To determine if changes in LFI were associated with structural changes of lymphatic vessels such as vessel density within donor grafts, vessels were stained with the lymphatic endothelial cell marker LYVE-1 (Figure 2A through 2C). The number of myocardial lymphatic vessels increased 5-fold with time in the HY-mismatched grafts ( Figure 2D , with a mean of 11.75 versus 55 vessels per 10 MPF at week 1 and 10 posttransplant, respectively, P=0.038). Subepicardium lymphatic density also increased 3-fold in HY-mismatched grafts (Figure 2D , mean of 6.25 versus 18 per 10 MPF), suggesting that active lymphangiogenesis has occurred during chronic allograft inflammation.
The LYVE-1 + myocardial lymphatic vessel mean area showed an increase at week 5 in comparison with week 1 ( Figure 2E ) in the HY-mismatched grafts (mean 252.944 μm 2 versus 647.981 μm 2 , week 1 and week 5, respectively, P=0.0046), which was significantly enhanced in comparison with the sex-matched grafts . LYVE-1 + vessels density (D, *P=0.038) and myocardial (E, ****P<0.0001) and subepicardial (F, *P=0.0091) area (μm 2 ) was determined by 2 independent observers in at least 10 medium power fields, with area determined with Image J software. Data are shown as a mean of the 2 independent observations and 4 independent experiments±SEM; of sex-matched (GM) and HY-mismatched (HY) grafts at weeks 1, 5, and 10. The lymphatic flow index from each individual mouse was correlated with the corresponding LYVE-1 + vessel number (G, *P=0.0021) and area at week 1 (H, myocardium, HY ***P=0.0008, GM ***P=0.0003; I, subepicardium, HY ****P=0.0008, GM ***P=0.0003), week 5 (J, ****P<0.0001) and week 10 (K, *P=0.0222). To determine if vessels were of donor or recipient origin, immunofluorescence was performed with anti-LYVE-1 and anti-YFP. Donor lymphatic vessels are EYFP -and LYVE-1 + (L through S; white arrows). However, the transplant recipients express EYFP, and thus recipient lymphatic vessels are EYFP + and LYVE-1 + (T through W; yellow arrows). Shown are representative examples of lymphatic vessel staining in sex-matched grafts (L through O) and HYmismatched grafts (P through S) 10 weeks posttransplant. Representative high-power images showing a recipient lymphatic vessel within a donor organ are displayed in T through W. DAPI indicates 4ʹ,6-diamidino-2-phenylindole; Myo, myocardium; SPECT/CT, single photon emission computed tomography/computed tomography; and Sub, subepicardium.
(P<0.0001). However, by week 10, the average vessel area is reduced back to levels similar to week 1. The subepicardial lymphatic vessel area increased at week 10 in comparison with week 1 ( Figure 2F ; mean 207.354 μm 2 versus 469.297 μm 2 , week 1 and week 10, respectively, P=0.0255), which was significantly enhanced in comparison with the sex-matched grafts (P=0.0091).
LFI Correlates With Lymphatic Vessel Area, But Not Density
The higher density of lymphatic vessels within donor grafts has been reported previously; however, this does not necessarily mean higher lymphatic flow or, indeed, more efficient transport of DPL to dLN. We therefore correlated the LFI with the lymphatic vessel density. At week 1, the enhanced LFI observed in the sex-matched grafts correlated with the myocardial vessel density ( Figure 2G , P=0.0021). No correlation was observed between the LFI and lymphatic vessel number in either graft type at the later time points (Table 1) . However, because not all vessels have the same diameter, we therefore correlated LFI with the mean lymphatic vessel area. Overall, at all time points, the LFI correlated strongly with lymphatic vessel area ( Figure 2H through  2K) , with the exception of the subepicardium area in the HY mismatch at week 5 ( Figure 2J ). At week 1, in both graft types, enhanced myocardial lymphatic vessel area correlated with the LFI (Figure 2H , HY mismatch P=0.0008 and sex-matched P=0.0003); this was also the case for the subepicardial vessel area in the sexmatched grafts ( Figure 2I, P=0.008) . However, in the HY-mismatched grafts, the reduced LFI inversely correlated with enhanced subepicardial vessel area (Figure 2I, P<0.0001) . The enhanced LFI and myocardial vessel area both observed in the HY-mismatch grafts at week 5, resulted in the most statistically significant correlation ( Figure 2J , P<0.0001, R 2 =0.9861, r s =1), which was not observed in the sex-matched grafts. No correlation was observed for the subepicardium area in the HY mismatch at week 5 ( Figure 2J ). At 10 weeks after transplant in recipients of an HY-mismatch cardiac graft, the LFI did positively correlate with an increase in the mean myocardial and subepicardial lymphatic vessel area ( Figure 2K , HY mismatch P=0.0222 and sexmatched P=0.0222), suggesting that, at the later time points, it is increased area, not the number of vessels, that allows an increased flow out of the graft. 
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Donor Cells Are the Main Source of Neolymphangiogenesis in Cardiac Allografts
In fully major histocompatibility complex-mismatched transplantation models, lymphatic vessels are a combination of donor and recipient derived. 11 To determine if changes in LFI were attributable to the lymphangiogenesis of donor or recipient lymphatic vessels, donor hearts were stained for expression of EYFP, expressed only by the recipient. Colocalization of EYFP and LYVE-1 in sections obtained 10 weeks after surgery demonstrated that the vast majority of lymphatic vessels were donor derived ( Figure 
LFI Correlates With Trafficking of Donor Cells to dLNs
Migration of DPL out of donor organs to dLN is a key early event in the initiation of the immune response. To determine the number of donor cells that have migrated out of the grafts, we isolated genomic DNA from the mediastinal dLN to quantify the number of male donor cells present after transplantation by using a standard curve generated by real-time polymerase chain reaction ( Figure 3A) . One week posttransplant, 1708±1324 male donor cells (Figure 3B , P=0.0019), being 0.12±0.07% of the recipient cells ( Figure 3C P=0.0019), were detected in the mdLN following transplantation. The percentage of male donor cells present in dLN of recipients strongly correlated with LFI ( Figure 3D and Table 2 ; P<0.0001, r s =1), and the number of CD8 + cells, as well, within the donor graft in the same recipients ( Figure 3e and Table 2 ; P=0.0081, r s =1), suggesting that higher lymphatic flow rate does facilitate trafficking of DPL and the subsequent immune response.
Cardiac Allograft Vasculopathy Correlates With Increased Lymphatic Vessel Area and Infiltrating CD8 + T Cells
Because the LFI correlates with trafficking of donor cells to dLN, and we have previously demonstrated that DPLs elicit a donor-specific CD8 + T-cell response in the mdLN, 8 we hypothesized that the initial variation in LFI from donor grafts to the mdLN could alter the subsequent priming of the immune response and, thus, cellular infiltration into the graft, and this, in turn, would lead to graft vasculopathy. Over the time course, the number of CD4 + ( Figure 4A and 4D), CD8 + ( Figure 4B and 4E), and CD68 + ( Figure 4C and 4F) cells increased in the grafts of HY-mismatched recipients. At the earlier time points, small numbers of CD4 + , CD8 + , and CD68 + cells were seen in the sex-matched grafts, but inflammation had resolved after 4 weeks (Figure 4 ). In the HY-mismatched graft at week 5 CD68 + macrophages were the predominant infiltrating cell population ( Figure 4G ), which mirrors the HY-mismatched LFI ( Figure 1L ) and myocardial vessel area ( Figure 2E and 2J) . The percentage of CD8 + cells increased over time in the HY-mismatched graft ( Figure 4G ) and was consistently higher than the sexmatched graft ( Figure 4H ). Cellular infiltration was reflected in graft damage as evident by the development of CAV, determined by vessel luminal occlusion ( Figure 4I through 4K), which increased in the transplanted graft over time ( Figure 4L, P<0.0001 ). There was a strong correlation between CAV and the number of CD8 + T cells within the HY-mismatched grafts ( Figure 4M , Table 3 ; P<0.0001, r s =1), and the mean lymphatic vessel area, as well ( Figure 4N , P<0.0001, Table 3 ; r s =1).
The LFI and Increased Lymphatic Vessel Area Correlate With Inflammatory Infiltrate in Cardiac Grafts
Differences in lymphatic flow from donor grafts are likely to have an influence on the inflammatory response. Likewise, the severity of the inflammatory response may also affect lymphangiogenesis and lymphatic flow. We therefore correlated LFI and lymphatic vessel area with inflammatory infiltrates within the donor grafts. Results are summarized in Table 4 . Overall, with HY-mismatch grafts, enhanced LFI and increased lymphatic area, respectively, correlated with enhanced CD8 + T-cell infiltration at week 1 ( Figure 4O , P=0.0008 and Figure 4P , P<0.0001) and at week 10 ( Figure 4Q , P=0.0218 and Figure 4R , myocardium P=0.0060, subepicardium P=0.0004). Enhanced CD4 + T-cell infiltra- tion also correlated with increased lymphatic area in HY-mismatched grafts in the subepicardium at week 1 ( Figure 4S , P<0.0001) and myocardium at week 10 (Figure 4T, P=0.0206) . It is interesting to note that there is an inverse correlation with CD4 + T cells ( Figure 4S ) and CD68 + macrophages ( Figure 4U , P=0.0016, r s =0.8) and the myocardial vessel area at week 1 and the number of CD68 + macrophages at week 10 ( Figure 4V , myocardium P<0.0001, subepicardium P=0.0008). This may be attributable to the early processes of lymphangiogenesis, where macrophages transdifferentiate into lymphatic endothelial cells 11 and CD4 + T cells increase lymphangiogenesis via VEGF-A and VEGF-C expression. 27 Altogether this is indicative that the chronic inflammatory environment, in combination with the increased lymphatic vessel area, has allowed increased trafficking to the mdLN and, in turn, inflammatory cell recruitment to the graft.
DISCUSSION
Development of CAV is the main limitation of longterm survival of patients with heart transplants. 4 It is hypothesized that CAV is a result of interrupted lymphatic drainage after surgery. 9 We used SPECT/CT lymphoscintigraphy to provide an objective quantification of lymphatic flow following transplantation and correlated it with the immune response. It is important to note that the parameters measured result in an index, not an actual quantification of lymphatic flow rate in terms of volume per unit time. Nonetheless, it provides an objective quantification of lymph flow and allows us to compare flow rates between allografts and correlate this with lymphatic density within the donor graft and other immunologic events. We have chosen a single minor antigen (HY) mismatched model to allow time for chronic rejection to develop and any changes in lymphatic vessels within the donor graft to take place. 26 Minor antigens are only recognized by the recipient via the indirect pathway of antigen presentation, a route associated with chronic rejection. 28 After organ transplantation, donor lymphatics reconnect to the local lymphatic network of the recipient. It is now well established that, on the transplantation of organs into the abdomen, the donor organ lymphatics connect to the subdiaphragmatic network of the recipient, which drains to the mediastinal LN, 8, [29] [30] [31] [32] rather than lymphatic chains more locally, such as the mesenteric Figure 4 Continued. Positive CD4 (D, **P=0.0079) and CD8 (E, W5GM**P=0.0019, W5HY**P=0.0066, W10HY**P=0.0429, W1GM versus HY**P=0.0077, W10GM versus HY*P=0.0233) cells were counted in 20 random highpower fields (magnification 400×) by 2 independent observers. For CD68 + macrophage staining (F, W10**P=0.0079), a 63-point grid was overlaid onto a 400× magnification of macrophage staining. The percentages of grid points positive for CD68 staining were counted by 2 independent observers. Data are shown as the mean number of cells, per field of view (FoV), of the 2 independent observations and 4 independent experiments±SEM, of a sex-matched and HY-mismatched grafts at weeks 1, 5, and 10. Within the infiltrating cells, the percentage of CD68 + , CD4 + , and CD8 + cells was determined in the HY-mismatched (G) and sex-matched grafts (H). Immunohistochemical staining for Elastic Van Gieson was performed to determine graft vasculopathy. Shown is a representative of a sex-matched (I) and HY-mismatched grafts (J and K). Histologically the allograft vasculopathy ranged from median (J) to severe (K) in the HY-mismatched graft. Characterized by inflammatory cell invasion into the layers of the internal to external elastic, shown is the lumen of the vessel (L), the internal elastic (I), and the external elastic (E). Measurement of the internal elastic (I) and the external elastic (E) can be used to calculate the percentage of luminal occlusion (L, W1*P=0.0121, W5*P=0.0357, and W10*P=0.0238; ****P<0.0001). Shown is the percentage luminal occlusion in 4 independent experiments with mean at 1, 5, and 10 weeks. The percentage luminal occlusion was correlated with CD8 + cell number (M, ****P<0.0001) and the mean lymphatic vessel area (N, ****P<0.0001). CD8 + cell number was correlated with the LFI (O, W1****P<0.0001 and Q, W10*P=0.0218) and the lymphatic vessel area (P, myocardial W1****P<0.0001, subepicardial W1***P=0.0008 and R, myocardial W10**P=0.006, subepicardial W10***P=0.0004). CD4 + cell number was correlated with the lymphatic vessel area (S, myocardial W1*P=0.0287 and subepicardial W1****P<0.0001 and T, W10*P=0.0206). CD68 + cell number was correlated with the lymphatic vessel area (U, W1**P=0.0016) and density (V, myocardial W10****P<0.0001 and subepicardial W10***P=0.0008). GM indicates sexmatched; LFI, lymphatic flow index; SPECT/CT, single photon emission computed tomography/computed tomography; W1, week 1; W5, week 5; and W10, week 10. chain. The reason for this is unclear. To support this observation, we have previously demonstrated the presence of high numbers of donor-specific T cells in the mediastinal LN, but not in irrelevant nondraining LN. Occasionally, mesenteric LNs contain a small population of donor-specific T cells, but it is not a constant feature. 8 For orthotropic heart transplant, as in the clinical situation, donor lymphatics will drain to the local dLN. Although the exact sites may not be well established, the immunologic effect should not be the same wherever the donor lymph drains, because the dLNs merely provide a niche for the donor antigens to meet their cognate alloreactive T cells, which, after activation, traffic via blood to the donor graft, resulting in rejection.
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The key question we set out to address is whether the higher density of lymphatic vessels observed within donor organs after transplantation is associated with enhanced lymphatic flow or more efficient transport of DPL to the dLN, leading to enhanced alloimmunity, ie, do changes in lymphatic structure result in changes in function?
In our model, there was an increase in lymphatic density, in concordance with other models of cardiac 4 and kidney 33, 34 mouse and rat transplantation ( Figure 2 ). However, others have shown a lower density of lymphatics correlated with rejection in human and rat cardiac allografts. 13, 16, 35 This may be because of differences in timing or location within the graft; for example, in a rat allograft model 13 in agreement with our data, a significant increase in vessel density is observed within the inner lymphatics; however, a decrease is observed in the outer lymphatics. Indeed, variations between different models may indicate that determining vessel density by histology alone may not be a reliable indicator of graft rejection.
We found a higher LFI in the sex-matched group in comparison with the HY-mismatched group at week 1 (Figure 1 ), which correlated with enhanced lymphatic vessel number ( Figure 2G ), and the myocardial and subepicardial areas, as well ( Figure 2H through 2K) . The reason for this is unclear, but lymphatic flow out of the graft in the sex-matched recipients may lead to beneficial effects such as resolving tissue edema and promoting the clearance of inflammatory cells and cytokines to resolve local inflammation, 32, 36 which does not occur in the HY-mismatch recipients. 37 At week 1, enhanced LFI inversely correlated with reduced subepicardial lymphatic vessel area in the HY-mismatched graft (Figure 2I ). An edema with enhanced cell and fluid load may well be present because of inflammation in the HY graft, which results in increased contractile pressure and lymph flow through the smaller vessels.
The increase in LFI in the HY-mismatched donor grafts in comparison with sex-matched grafts at weeks 5 and 10 ( Figure 1) is not surprising, given that the number of lymphatic vessels is increased, potentially allowing more flow of lymph out of the grafts. However, the difference between the HY-mismatched and sex-matched grafts was surprising and is disproportionate to the difference in lymphatic vessel density observed between the 2 groups, suggesting that additional factors, such as the inflammatory milieu within HY-mismatched grafts, may play a role in increasing the lymphatic flow. Furthermore, the LFI correlated with lymphatic vessel area, not density ( Figure 2 and Table 1 ). The low LFI to the mdLN in sex-matched recipients was not attributable to drainage to a different set of dLN and, therefore, was missed by the SPECT/CT scans as evident from the SPECT/CT scans, showing a slow rate of Nanocoll leaving the grafts, especially at week 10 ( Figure 1M ).
In the HY-mismatch recipients, the myocardial lymphatic vessel area peaked at week 5 and decreased subsequently ( Figure 2E) ; the percentage of infiltrating CD68 + macrophages corresponded with this ( Figure 4G ), which also mirrored a peak at week 5 in the LFI ( Figure 1L and Figure 2J ), indicative that the macrophages may play a role in increasing the vessel area by transdifferentiation and de novo lymphangiogenesis.
11 Lymphatic density increased with time ( Figure 2D) ; however, despite an increase in density at week 10, the LFI decreased. In a model of cutaneous hypersensitivity, inflammatory-driven lymphatic endothelial cell proliferation and lymphatic remodeling did not affect the lymphatic vessel density, but vessels increased in size, affecting lymph flow. 38 In addition, to physical factors such as vessel area, lymph flow is regulated by complex interactions of phasic and sustained tonic contractions of the lymphatic smooth muscles, where force and frequency of lymphatic contraction can be influenced by a variety of signals including cytokines. 37 Therefore, the active inflammation and enhanced myocardial lymphatic area, observed in week 5, may result in the enhanced lymphatic flow observed here.
Previously, in both abdominal and cervical transplantation, we have shown leakage from the open severed ends of the lymphatic vessel drains into mdLN and that intact lymphatic vessels are not essential for flow toward these particular dLNs. 8 By week 5, the lymphatic vessels have reconnected, and we speculate, therefore, that there is no longer any leak into the peritoneum in the sex-matched recipients. However, in the HY-mismatch recipients, because of the process of inflammatorydriven lymphangiogenesis, we observe the lymphatic vessels enlarge (Figure 2E ), presumably becoming leaky and allowing lymph to continue to traffic to the mdLN.
We found that LFI at the earliest time point (week 1) strongly correlated with the percentage of male donorderived cells determined to be present in the mdLN (Figure 3C) . This, in turn, correlated with increased numbers of CD8 + T cells within the donor graft ( Figure 3E ). The number of CD8 + T cells within the HY-mismatched grafts correlated with the level of CAV, determined by vessel occlusion ( Figure 4M ). Furthermore, CAV correlated with the mean lymphatic vessel area ( Figure 4N ). There is also a positive correlation with the increased ORIGINAL RESEARCH ARTICLE CD8 + T cells and LFI at weeks 1 ( Figure 4O ) and 10 (Figure 4Q) , and the mean lymphatic vessel area at weeks 1 ( Figure 4P ) and 10 ( Figure 4R ). Increased numbers of CD4 + T cells also correlated with the lymphatic vessel area in the subepicardium at week 1 ( Figure 4S ) and the myocardium at week 10 ( Figure 4T ). In combination, these data support the notion that increased lymphatic flow is associated with increased trafficking of DPL to dLN, which leads to an enhanced subsequent alloimmune response, which we have shown previously in our model is CD8 + T-cell driven. 8 In support of this, in a study of human renal transplants, 34 rejection was caused by a lymphocyte-rich inflammatory infiltrate, attracted by CCL21 produced by lymphatic endothelial cells. The authors speculated that neolymphangiogenesis contributed to the export of antigen-presenting cells, which in turn induced an alloreactive immune response. 34 Furthermore, Lakkis et al 39 concluded that the rejection process is dependent on a suitable niche for interactions between antigen-presenting cells and recipient T cells, with rejection being considerably delayed in mice lacking lymph nodes, and completely halted in alymphoplastic splenectomized recipients.
The lymphatic vessel area may be enhanced by the previously reported process of B-cell-driven lymphangiogenesis. 40 In our model of CAV, we found evidence that the early process of lymphangiogenesis appears to be attributable to the numbers of CD4 + T cells and CD68 + macrophages resident in the graft (Table 4 and Figure 4G and 4S through 4V). CD4 + T cells have been previously shown to increase lymphatic vessels density through increased expression of VEGF-A and VEGF-C. 27 Furthermore, macrophages have been shown to play a role in de novo lymphangiogenesis. 11 Our results indicate that most of the lymphatic vessels were of donor rather than recipient origin (Figure 2A through 2I ). This is in concordance with some published data, 4, 11 but not others. 41 These differences may be because of the different models used. Kerjaschki et al 11 demonstrated that de novo lymphangiogenesis involved incorporation of recipient-derived lymphatic progenitors, derived from infiltrating macrophages in human kidney allografts. Our model is a single minor antigen mismatch, which results in only a moderate degree of inflammation, which may not be enough to result in a high proportion of recipient-derived lymphatic vessels.
We attempted to correlate LFI with the antidonor response, such as graft infiltration at later time points. Overall, positive correlations were found (Tables 1  through 4 and Figure 4 ). However, these data must be interpreted with care, because LFI and the donor response are clearly interdependent, with each having the potential to enhance the other. Therefore, the data presented here do not provide evidence for cause and effect but, nonetheless, provide some insight into the complex interplay between lymphatic function and the inflammatory response.
In conclusion, the LFI provides a functional assessment of lymphatic flow following transplant. Lymphatic flow is enhanced in HY-mismatched grafts in comparison with sex-matched grafts to a degree that cannot be accounted for by the increased lymphatic vessel density alone, implying that inflammation may enhance the flow of lymph. Because ischemia/reperfusion injury affects lymphatic flow from the heart, and this change is seen before myocardial necrosis is visible, changes in lymphatic drainage could be an early marker of heart disease and allow for an early diagnosis. 42, 43 Therefore, SPECT-CT imaging could prove to be an extremely useful tool in transplantation research and in clinical investigation with the potential to be adapted to detect early heart disease. Despite advances in graft survival rate, there is still a need for targeted suppression of alloimmunity and subsequent eradication of CAV and rejection. The data suggest that interference of lymphatic flow to the mdLN at the time of transplant would promote graft survival. Preclinical models using donors with disrupted lymphatics would definitively prove this point. Treatment with inhibitors of lymphatic flow or lymphangiogenesis (eg, postharvest using complement fixing anti-LYVE-1 antibodies) could be used as a first step to treat patients who have received a heart transplant, as used in other disease models, 44, 45 and can be adapted for use in transplantation. Circulation is available at http://circ.ahajournals.org.
